

# Resource Summary Report

Generated by T1D on Aug 9, 2026

## Tecan: Infinite M Plex microplate reader

RRID:SCR\_026522

Type: Tool

---

### Proper Citation

Tecan: Infinite M Plex microplate reader (RRID:SCR\_026522)

---

### Resource Information

**URL:** <https://shop.tecan.com/us/en/product/30190085/Infinite-M-Plex-multimode-microplate-reader-monochromator-optics>

**Proper Citation:** Tecan: Infinite M Plex microplate reader (RRID:SCR\_026522)

**Description:** Multimode microplate reader with monochromator optics. Offers free wavelength selection and scanning capabilities. Used for all standard absorbance, fluorescence and luminescence assays.

**Resource Type:** instrument resource

**Keywords:** Multimode microplate reader, monochromator optics, standard absorbance assays, fluorescence assays, luminescence assays,

**Specification URL:** [https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR\\_026522.pdf](https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_026522.pdf)

**Resource Name:** Tecan: Infinite M Plex microplate reader

**Resource ID:** SCR\_026522

**Alternate IDs:** Model\_Number\_Infinite\_M\_Plex

**Record Creation Time:** 20250305T060326+0000

**Record Last Update:** 20260808T190748+0000

---

### Ratings and Alerts

No rating or validation information has been found for Tecan: Infinite M Plex microplate reader.

No alerts have been found for Tecan: Infinite M Plex microplate reader.

## Data and Source Information

**Source:** [SciCrunch Registry](#)

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [T1D](#) .

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. *Cancer discovery*, 16(5), 895.

Yemelyanenko J, et al. (2026) C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3. *Cancer research*, 86(6), 1372.

Grafals-Ruiz N, et al. (2026) M6 metabolite contributes to the efficacy of the Rac/Cdc42 inhibitor MBQ-167 in metastatic breast cancer. *Molecular cancer therapeutics*.

Sinyavskiy S, et al. (2026) Benzo[e][1,2,4]triazolo[1,5-c][1,2,3]triazines: Design, Synthesis, and Cytotoxic Effects. *Chemistry & biodiversity*, 23(6), e71416.

Brea EJ, et al. (2025) Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors. *Cancer immunology research*, 13(11), 1749.

Baas JD, et al. (2025) Distinct cAMP Regulation in Scleroderma Lung and Skin Myofibroblasts Governs Their Dedifferentiation via p38?? Inhibition. *FASEB journal* : official publication of the Federation of American Societies for Experimental Biology, 39(12), e70762.